Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Feifei Teng

Showing results (21-30 of 54) with videos related to

Pageof 6
Sort By:
Thoracic Cancer|February 20, 2024
Using MRI radiomics to predict the efficacy of immunotherapy for brain metastasis in patients with small cell lung cancerXiaonan Shi, Peiliang Wang, Yikun Li, et al.
Journal of Cancer Research and Clinical Oncology|April 10, 2026
The efficacy and toxicity of TRT on metastatic NSCLC in patients treated with targeted therapy and chemoimmunotherapyLishan Xue, Jinquan Yao, Qian Xu, et al.
Frontiers in Immunology|June 13, 2024
Editorial: Novel immune markers and predictive models for immunotherapy and prognosis in breast and gynecological cancersFuhao Wang, Qingyu Huang, Shicheng Guo, et al.
Future Oncology (London, England)|March 7, 2020
The post-treatment neutrophil-to-lymphocyte ratio and changes in this ratio predict survival after treatment of stage III non-small-cell lung cancer with conventionally fractionated radiotherapyDuoying Wang, Dong Guo, Aijie Li, et al.
Cancer Management and Research|August 14, 2019
Expression and prognostic role of IKBKE and TBK1 in stage I non-small cell lung cancerXin Wang, Feifei Teng, Jie Lu, et al.
Medcomm|May 19, 2023
Optimum fractionation of radiation to combine PD-1 blockadeFeifei Teng, Tianwen Yin, Xiao Ju, et al.
Cancer Letters|July 10, 2017
PD-1/PD-L1 checkpoint blockades in non-small cell lung cancer: New development and challengesXiangjiao Meng, Yanli Liu, Jianjun Zhang, et al.
Frontiers in Oncology|April 1, 2021
Efficacy and Safety of Anti-PD-1 Plus Anlotinib in Patients With Advanced Non-Small-Cell Lung Cancer After Previous Systemic Treatment Failure-A Retrospective StudyPeiliang Wang, Xiaozhuang Fang, Tianwen Yin, et al.
Oncotargets and Therapy|February 19, 2016
PD-1/PD-L1 blockades in non-small-cell lung cancer therapyWang Jing, Miaomiao Li, Yan Zhang, et al.
Frontiers in Immunology|April 30, 2024
Development and validation of an MRI-Based nomogram to predict the effectiveness of immunotherapy for brain metastasis in patients with non-small cell lung cancerJunhao Xu, Peiliang Wang, Yikun Li, et al.
Pageof 6

Showing results (21-30 of 54) with videos related to

Sort By:
Pageof 6
Thoracic Cancer|February 20, 2024
Using MRI radiomics to predict the efficacy of immunotherapy for brain metastasis in patients with small cell lung cancerXiaonan Shi, Peiliang Wang, Yikun Li, et al.
Journal of Cancer Research and Clinical Oncology|April 10, 2026
The efficacy and toxicity of TRT on metastatic NSCLC in patients treated with targeted therapy and chemoimmunotherapyLishan Xue, Jinquan Yao, Qian Xu, et al.
Frontiers in Immunology|June 13, 2024
Editorial: Novel immune markers and predictive models for immunotherapy and prognosis in breast and gynecological cancersFuhao Wang, Qingyu Huang, Shicheng Guo, et al.
Future Oncology (London, England)|March 7, 2020
The post-treatment neutrophil-to-lymphocyte ratio and changes in this ratio predict survival after treatment of stage III non-small-cell lung cancer with conventionally fractionated radiotherapyDuoying Wang, Dong Guo, Aijie Li, et al.
Cancer Management and Research|August 14, 2019
Expression and prognostic role of IKBKE and TBK1 in stage I non-small cell lung cancerXin Wang, Feifei Teng, Jie Lu, et al.
Medcomm|May 19, 2023
Optimum fractionation of radiation to combine PD-1 blockadeFeifei Teng, Tianwen Yin, Xiao Ju, et al.
Cancer Letters|July 10, 2017
PD-1/PD-L1 checkpoint blockades in non-small cell lung cancer: New development and challengesXiangjiao Meng, Yanli Liu, Jianjun Zhang, et al.
Frontiers in Oncology|April 1, 2021
Efficacy and Safety of Anti-PD-1 Plus Anlotinib in Patients With Advanced Non-Small-Cell Lung Cancer After Previous Systemic Treatment Failure-A Retrospective StudyPeiliang Wang, Xiaozhuang Fang, Tianwen Yin, et al.
Oncotargets and Therapy|February 19, 2016
PD-1/PD-L1 blockades in non-small-cell lung cancer therapyWang Jing, Miaomiao Li, Yan Zhang, et al.
Frontiers in Immunology|April 30, 2024
Development and validation of an MRI-Based nomogram to predict the effectiveness of immunotherapy for brain metastasis in patients with non-small cell lung cancerJunhao Xu, Peiliang Wang, Yikun Li, et al.
Pageof 6